Related Experiment Video
Updated: Aug 4, 2026

12:55
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
Published on: January 17, 2015
High-throughput generation and engineering of recombinant human antibodies
B Krebs1, R Rauchenberger, S Reiffert
1MorphoSys AG, Lena-Christ-Strasse 48, 82152 Martinsried, Germany.
Journal of Immunological Methods
|June 19, 2001
Summary
The Human Combinatorial Antibody Library (HuCAL) provides a high-throughput method for developing human antibodies. This optimized library facilitates antibody engineering and diverse applications.
Area of Science:
- Biotechnology
- Immunology
- Molecular Biology
Background:
- The Human Combinatorial Antibody Library (HuCAL) is a single-chain fragment variable (scFv)-based phage display library.
- It comprises 2x10^9 members optimized for high-throughput generation and engineering of human antibodies.
Purpose of the Study:
- To demonstrate the feasibility of automated, miniaturized screening of the HuCAL-scFv library.
- To highlight the library's modular design for converting scFv into various antibody formats and fusions.
- To showcase HuCAL as a convenient source for diverse human antibody applications.
Main Methods:
- Utilizing a single-chain Fv-based phage display library (HuCAL-scFv) with 2x10^9 members.
- Expressing antibodies in high levels in Escherichia coli for automated panning and screening.
- Employing a modular design for converting scFv into Fab, miniantibody, and immunoglobulin formats.
Main Results:
- 61% of the library genes code for functional scFv antibodies.
- High-level expression in E. coli enables automated, miniaturized screening (96- and 384-well formats).
- Facilitated conversion into multiple formats and fusion with effector functions/tags.
Conclusions:
- The HuCAL principle enables rapid, high-throughput development of human antibodies.
- HuCAL-scFv is suitable for automated screening and engineering.
- The library's modularity supports diverse therapeutic and research applications.
More Related Videos
Related Concept Videos
Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...

